A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
An Open-label, Dose Escalation and Expansion, Phase 1/2 Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of TAK- 188, an Anti-CCR8 Antibody-Drug- Conjugate, as a Single Agent in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Takeda
This observational or N/A phase trial investigates Advanced or Metastatic Solid Tumors and is currently actively recruiting participants. Takeda leads this study, which shows 5 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Apr 28, 2026 — Present [daily]
Recruiting
-
Apr 17, 2026 — Apr 28, 2026 [daily]
Recruiting
Phase: PHASE1/PHASE2 → None
-
Feb 2026 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE1/PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2025 — Jan 2026 [monthly]
Not Yet Recruiting PHASE1/PHASE2
First recorded
Eligibility Summary
TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 may help to remove these Tregs. Removing these Tregs may allow more cancer-fighting cells (CD8+ T cells) to attack the tumor and potentially stop tumors from growing. In this study, researchers want to learn if TAK-188 can help the body's immune system better fight cancer in adults with advanced cancers which have not gotten better with regular treatments. The main aims of this study are to check if TAK-188 is safe in adults with advanced or spreading (metastatic) solid tumors, if participants tolerate the treatment with TAK-188 and to learn if TAK-188 works well in adults with certain advanced cancers after their previous treatments didn't work. Participants may receive TAK-188 for up to 1 year. Their health will be monitored after the treatment has ended for up to another year.
Contact Information
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .